{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T12:48:13Z","timestamp":1785761293456,"version":"3.56.0"},"reference-count":75,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"FCT\u2014Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["2021.07538.BD"],"award-info":[{"award-number":["2021.07538.BD"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"award":["2021.07538.BD"],"award-info":[{"award-number":["2021.07538.BD"]}],"id":[{"id":"https:\/\/ror.org\/00snfqn58","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Indiana University Melvin and Bren Simon Comprehensive Cancer Center","award":["2987602"],"award-info":[{"award-number":["2987602"]}]},{"award":["2987602"],"award-info":[{"award-number":["2987602"]}],"id":[{"id":"https:\/\/ror.org\/00g1d7b60","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background\/Objectives: Ubiquitin-specific protease 7 (USP7) is a deubiquitinating enzyme that regulates multiple oncogenic and tumor-suppressive pathways and has emerged as a promising target for anticancer drug discovery. However, most reported USP7 inhibitors belong to a limited number of structural classes, and no USP7-targeted therapy has yet reached clinical application. This study aimed to identify structurally diverse candidate USP7-inhibitory scaffolds with antiproliferative activity using an integrated computational and experimental screening strategy. Methods: A drug discovery workflow combining pharmacophore modelling, structure-based virtual screening, molecular docking, and in silico pharmacokinetic assessment was employed to identify candidate USP7 inhibitors. Selected compounds were evaluated for inhibition of recombinant USP7 and for antiproliferative activity in a panel of human cancer cell lines. Molecular docking analyses were performed to investigate predicted binding modes. Results: The primary screening campaign identified four active compounds (&gt;50% inhibition at 10 \u00b5M) and twenty-one weakly active compounds (10\u201349% inhibition at 10 \u00b5M), including structurally distinct approved drugs and compounds from an in-house chemical library. The four active compounds were subsequently validated by dose\u2013response assays against recombinant USP7 and exhibited micromolar inhibitory activity. These candidate USP7-inhibitory scaffolds also exhibited antiproliferative activity across cancer cell lines with different molecular backgrounds. Docking studies predicted binding within a pharmacologically relevant region of the USP7 catalytic cleft and revealed putative interactions with key residues involved in ligand recognition. Among the compounds evaluated, rafoxanide demonstrated the most favorable combination of predicted USP7 binding and antiproliferative activity. Conclusions: This integrated virtual screening and experimental validation approach enabled the identification of candidate USP7-inhibitory scaffolds with preliminary antiproliferative activity. The identified hits include approved drugs with previously unreported USP7 inhibitory activity, as well as underexplored scaffolds that expand the chemical space of candidate USP7-targeting molecules. These candidate scaffolds warrant further medicinal chemistry optimization, orthogonal validation, and mechanistic characterization to establish their potential as USP7-targeted anticancer agents.<\/jats:p>","DOI":"10.3390\/ph19081219","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T11:50:21Z","timestamp":1785757821000},"page":"1219","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Virtual Screening\u2013Guided Identification of Candidate USP7-Inhibitory Scaffolds Exhibiting Antiproliferative Activity"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1511-4364","authenticated-orcid":false,"given":"Rita I.","family":"Oliveira","sequence":"first","affiliation":[{"name":"Laboratory of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Coimbra, 3000-548 Coimbra, Portugal"},{"name":"Center for Neuroscience and Cell Biology, Center for Innovative Biomedicine and Biotechnology, University of Coimbra, 3060-197 Cantanhede, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2467-9401","authenticated-orcid":false,"given":"Caio","family":"Franco","sequence":"additional","affiliation":[{"name":"Center for Neuroscience and Cell Biology, Center for Innovative Biomedicine and Biotechnology, University of Coimbra, 3060-197 Cantanhede, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Mano","sequence":"additional","affiliation":[{"name":"Center for Neuroscience and Cell Biology, Center for Innovative Biomedicine and Biotechnology, University of Coimbra, 3060-197 Cantanhede, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6472-2879","authenticated-orcid":false,"given":"Ana S.","family":"Leal","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Indiana University School of Medicine, Indianapolis, IN 46202, USA"},{"name":"Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University, Indianapolis, IN 46202, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0779-6083","authenticated-orcid":false,"given":"Jorge A. R.","family":"Salvador","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Coimbra, 3000-548 Coimbra, Portugal"},{"name":"Center for Neuroscience and Cell Biology, Center for Innovative Biomedicine and Biotechnology, University of Coimbra, 3060-197 Cantanhede, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/sj.cdd.4401702","article-title":"The ubiquitin system for protein degradation and some of its roles in the control of the cell division cycle","volume":"12","author":"Hershko","year":"2005","journal-title":"Cell Death Differ."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.pharmthera.2014.11.002","article-title":"Deubiquitinase inhibition as a cancer therapeutic strategy","volume":"147","author":"Wang","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41418-020-00648-0","article-title":"Ubiquitin signaling in cell cycle control and tumorigenesis","volume":"28","author":"Dang","year":"2021","journal-title":"Cell Death Differ."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.molcel.2010.09.019","article-title":"The DNA damage response: Making it safe to play with knives","volume":"40","author":"Ciccia","year":"2010","journal-title":"Mol. Cell"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/cr.2016.39","article-title":"Ubiquitin modifications","volume":"26","author":"Swatek","year":"2016","journal-title":"Cell Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/nrm3143","article-title":"Ubiquitylation in apoptosis: A post-translational modification at the edge of life and death","volume":"12","author":"Vucic","year":"2011","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/cr.2016.40","article-title":"Ubiquitin signaling in immune responses","volume":"26","author":"Hu","year":"2016","journal-title":"Cell Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/17501911.2025.2501524","article-title":"Ubiquitin proteasome system (UPS): A crucial determinant of the epigenetic landscape in cancer","volume":"17","author":"Roy","year":"2025","journal-title":"Epigenomics"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41392-020-0107-0","article-title":"The role of ubiquitination in tumorigenesis and targeted drug discovery","volume":"5","author":"Deng","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1038\/s41467-022-30376-7","article-title":"Deubiquitinating enzymes and the proteasome regulate preferential sets of ubiquitin substrates","volume":"13","author":"Trulsson","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Oliveira, R.I., Guedes, R.A., and Salvador, J.A.R. (2022). Highlights in USP7 inhibitors for cancer treatment. Front. Chem., 10.","DOI":"10.3389\/fchem.2022.1005727"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1080\/14728222.2023.2266571","article-title":"Ubiquitin-specific protease 7 (USP7): An emerging drug target for cancer treatment","volume":"27","author":"Carreira","year":"2023","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"116323","DOI":"10.1016\/j.biopha.2024.116323","article-title":"Ubiquitin-specific proteases: From biological functions to potential therapeutic applications in gastric cancer","volume":"173","author":"Li","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.molcel.2011.06.034","article-title":"Mechanism of USP7\/HAUSP activation by its C-terminal ubiquitin-like domain and allosteric regulation by GMP-synthetase","volume":"44","author":"Faesen","year":"2011","journal-title":"Mol. Cell"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jsb.2016.05.005","article-title":"Structure of USP7 catalytic domain and three Ubl-domains reveals a connector alpha-helix with regulatory role","volume":"195","author":"Kim","year":"2016","journal-title":"J. Struct. Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/s41467-018-08231-5","article-title":"Kinetic analysis of multistep USP7 mechanism shows critical role for target protein in activity","volume":"10","author":"Kim","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S1097-2765(04)00157-1","article-title":"A dynamic role of HAUSP in the p53-Mdm2 pathway","volume":"13","author":"Li","year":"2004","journal-title":"Mol. Cell"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nature07290","article-title":"The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network","volume":"455","author":"Song","year":"2008","journal-title":"Nature"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.immuni.2013.05.018","article-title":"Stabilization of the transcription factor Foxp3 by the deubiquitinase USP7 increases Treg-cell-suppressive capacity","volume":"39","author":"Fleskens","year":"2013","journal-title":"Immunity"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"ra80","DOI":"10.1126\/scisignal.2001462","article-title":"DNMT1 stability is regulated by proteins coordinating deubiquitination and acetylation-driven ubiquitination","volume":"3","author":"Du","year":"2010","journal-title":"Sci. Signal."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ebiom.2016.10.018","article-title":"Ubiquitin-specific Protease-7 Inhibition Impairs Tip60-dependent Foxp3+ T-regulatory Cell Function and Promotes Antitumor Immunity","volume":"13","author":"Wang","year":"2016","journal-title":"eBioMedicine"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1172\/JCI85747","article-title":"Stabilization of histone demethylase PHF8 by USP7 promotes breast carcinogenesis","volume":"126","author":"Wang","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1038\/s41418-023-01180-7","article-title":"Inhibition of USP7 induces p53-independent tumor growth suppression in triple-negative breast cancers by destabilizing FOXM1","volume":"30","author":"Yi","year":"2023","journal-title":"Cell Death Differ."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"114917","DOI":"10.1016\/j.celrep.2024.114917","article-title":"USP7 deubiquitinates KRAS and promotes non-small cell lung cancer","volume":"43","author":"Huang","year":"2024","journal-title":"Cell Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.bcp.2017.02.011","article-title":"USP7 inhibitor P5091 inhibits Wnt signaling and colorectal tumor growth","volume":"131","author":"An","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1158\/0008-5472.CAN-24-3748","article-title":"Prostate Cancer Cells Secrete PD-1 in Exosomes to Enhance Myeloid-Derived Suppressor Cell Activity and Promote Tumor Immune Evasion","volume":"85","author":"Zhang","year":"2025","journal-title":"Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"110675","DOI":"10.1016\/j.jbc.2025.110675","article-title":"Ubiquitin-specific protease 7 promotes the growth and oncogenic potential of acute myeloid leukemia cells through the deubiquitination and upregulation of LRRK2","volume":"301","author":"Park","year":"2025","journal-title":"J. Biol. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ccr.2012.08.007","article-title":"A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance","volume":"22","author":"Chauhan","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1158\/1535-7163.MCT-09-0097","article-title":"Small-molecule inhibitor of USP7\/HAUSP ubiquitin protease stabilizes and activates p53 in cells","volume":"8","author":"Colland","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.chembiol.2011.08.018","article-title":"Activity-based chemical proteomics accelerates inhibitor development for deubiquitylating enzymes","volume":"18","author":"Altun","year":"2011","journal-title":"Chem. Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1021\/acs.jmedchem.7b00498","article-title":"Chemical Approaches to Intervening in Ubiquitin Specific Protease 7 (USP7) Function for Oncology and Immune Oncology Therapies","volume":"61","author":"Wu","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1021\/ml200276j","article-title":"Selective Dual Inhibitors of the Cancer-Related Deubiquitylating Proteases USP7 and USP47","volume":"3","author":"Weinstock","year":"2012","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature24451","article-title":"Molecular basis of USP7 inhibition by selective small-molecule inhibitors","volume":"550","author":"Turnbull","year":"2017","journal-title":"Nature"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"10056","DOI":"10.1021\/acs.jmedchem.7b01293","article-title":"Discovery of Small-Molecule Inhibitors of Ubiquitin Specific Protease 7 (USP7) Using Integrated NMR and in Silico Techniques","volume":"60","author":"Pastor","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"7914","DOI":"10.1021\/acs.jmedchem.5c00102","article-title":"Ubiquitin-Specific Protease 7 (USP7) as a Promising Therapeutic Target for Drug Discovery: From Mechanisms to Therapies","volume":"68","author":"Song","year":"2025","journal-title":"J. Med. Chem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1208\/s12248-012-9322-0","article-title":"Structure-based virtual screening for drug discovery: A problem-centric review","volume":"14","author":"Cheng","year":"2012","journal-title":"AAPS J."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Zhu, H., Zhang, Y., Li, W., and Huang, N. (2022). A Comprehensive Survey of Prospective Structure-Based Virtual Screening for Early Drug Discovery in the Past Fifteen Years. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232415961"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0092-8674(02)01199-6","article-title":"Crystal structure of a UBP-family deubiquitinating enzyme in isolation and in complex with ubiquitin aldehyde","volume":"111","author":"Hu","year":"2002","journal-title":"Cell"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"34289","DOI":"10.18632\/oncotarget.26136","article-title":"Molecular dynamics simulation reveals the possible druggable hot-spots of USP7","volume":"9","author":"Srivastava","year":"2018","journal-title":"Oncotarget"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1107\/S2053230X14002519","article-title":"A 2.2 A resolution structure of the USP7 catalytic domain in a new space group elaborates upon structural rearrangements resulting from ubiquitin binding","volume":"70","author":"Molland","year":"2014","journal-title":"Acta Crystallogr. Sect. F Struct. Biol. Commun."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.chembiol.2017.09.003","article-title":"Structure-Guided Development of a Potent and Selective Non-covalent Active-Site Inhibitor of USP7","volume":"24","author":"Lamberto","year":"2017","journal-title":"Cell Chem. Biol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"42717","DOI":"10.1038\/srep42717","article-title":"SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/17425255.2021.1865309","article-title":"Analyzing FDA-approved drugs for compliance of pharmacokinetic principles: Should there be a critical screening parameter in drug designing protocols?","volume":"17","author":"Pathania","year":"2021","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.cbpa.2018.05.010","article-title":"Opportunities and guidelines for discovery of orally absorbed drugs in beyond rule of 5 space","volume":"44","author":"Poongavanam","year":"2018","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrd3367","article-title":"Probing the links between in vitro potency, ADMET and physicochemical parameters","volume":"10","author":"Gleeson","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nrd4163","article-title":"The role of ligand efficiency metrics in drug discovery","volume":"13","author":"Hopkins","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.str.2017.11.010","article-title":"Selectively Modulating Conformational States of USP7 Catalytic Domain for Activation","volume":"26","author":"Ozen","year":"2018","journal-title":"Structure"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1021\/acsmedchemlett.7b00512","article-title":"Identification and Structure-Guided Development of Pyrimidinone Based USP7 Inhibitors","volume":"9","author":"Helm","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"5398","DOI":"10.1021\/acs.jmedchem.0c00245","article-title":"Discovery of Potent, Selective, and Orally Bioavailable Inhibitors of USP7 with In Vivo Antitumor Activity","volume":"63","author":"Leger","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"16622","DOI":"10.1021\/acs.jmedchem.2c01444","article-title":"Discovery of Orally Bioavailable N-Benzylpiperidinol Derivatives as Potent and Selective USP7 Inhibitors with In Vivo Antitumor Immunity Activity against Colon Cancer","volume":"65","author":"Li","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nchembio.2528","article-title":"Discovery and characterization of highly potent and selective allosteric USP7 inhibitors","volume":"14","author":"Gavory","year":"2018","journal-title":"Nat. Chem. Biol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1158\/1535-7163.MCT-20-0184","article-title":"Novel, Selective Inhibitors of USP7 Uncover Multiple Mechanisms of Antitumor Activity In Vitro and In Vivo","volume":"19","author":"Ohol","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"6582","DOI":"10.1021\/jm300687e","article-title":"Directory of useful decoys, enhanced (DUD-E): Better ligands and decoys for better benchmarking","volume":"55","author":"Mysinger","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1021\/acs.jcim.5b00559","article-title":"ZINC 15\u2014Ligand Discovery for Everyone","volume":"55","author":"Sterling","year":"2015","journal-title":"J. Chem. Inf. Model."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/BF00124456","article-title":"MAB, a generally applicable molecular force field for structure modelling in medicinal chemistry","volume":"9","author":"Gerber","year":"1995","journal-title":"J. Comput. Aided Mol. Des."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/jcc.10128","article-title":"Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. Parameterization and validation","volume":"23","author":"Jakalian","year":"2002","journal-title":"J. Comput. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1002\/jcc.20290","article-title":"The Amber biomolecular simulation programs","volume":"26","author":"Case","year":"2005","journal-title":"J. Comput. Chem."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nprot.2015.043","article-title":"The FTMap family of web servers for determining and characterizing ligand-binding hot spots of proteins","volume":"10","author":"Kozakov","year":"2015","journal-title":"Nat. Protoc."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"W271","DOI":"10.1093\/nar\/gks441","article-title":"FTMAP: Extended protein mapping with user-selected probe molecules","volume":"40","author":"Ngan","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1021\/acs.jcim.0c00121","article-title":"AutoPH4: An Automated Method for Generating Pharmacophore Models from Protein Binding Pockets","volume":"60","author":"Jiang","year":"2020","journal-title":"J. Chem. Inf. Model."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10822-008-9196-5","article-title":"Recommendations for evaluation of computational methods","volume":"22","author":"Jain","year":"2008","journal-title":"J. Comput. Aided Mol. Des."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1021\/ci8003978","article-title":"Better than random? The chemotype enrichment problem","volume":"49","author":"Mackey","year":"2009","journal-title":"J. Chem. Inf. Model."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13321-016-0189-4","article-title":"The power metric: A new statistically robust enrichment-type metric for virtual screening applications with early recovery capability","volume":"9","author":"Lopes","year":"2017","journal-title":"J. Cheminform."},{"key":"ref_64","unstructured":"Chemical Computing Group ULC (2023). Molecular Operating Environment (MOE), version 2022.02, Chemical Computing Group ULC."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.1021\/acs.jcim.9b00977","article-title":"Improving Docking-Based Virtual Screening Ability by Integrating Multiple Energy Auxiliary Terms from Molecular Docking Scoring","volume":"60","author":"Ye","year":"2020","journal-title":"J. Chem. Inf. Model."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"5912","DOI":"10.1021\/jm050362n","article-title":"A critical assessment of docking programs and scoring functions","volume":"49","author":"Warren","year":"2006","journal-title":"J. Med. Chem."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2174\/157340911795677602","article-title":"Molecular docking: A powerful approach for structure-based drug discovery","volume":"7","author":"Meng","year":"2011","journal-title":"Curr. Comput. Aided Drug Des."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1002\/cmdc.201200282","article-title":"Semisynthetic ursolic acid fluorolactone derivatives inhibit growth with induction of p21(waf1) and induce apoptosis with upregulation of NOXA and downregulation of c-FLIP in cancer cells","volume":"7","author":"Leal","year":"2012","journal-title":"ChemMedChem"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.1016\/j.bmc.2012.08.010","article-title":"Synthesis of novel ursolic acid heterocyclic derivatives with improved abilities of antiproliferation and induction of p53, p21waf1 and NOXA in pancreatic cancer cells","volume":"20","author":"Leal","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1039\/c3ob00011g","article-title":"Synthesis of novel heterocyclic oleanolic acid derivatives with improved antiproliferative activity in solid tumor cells","volume":"11","author":"Leal","year":"2013","journal-title":"Org. Biomol. Chem."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ejmech.2016.07.045","article-title":"Synthesis and cytotoxic activity of novel A-ring cleaved ursolic acid derivatives in human non-small cell lung cancer cells","volume":"123","author":"Mendes","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.ejmech.2017.08.058","article-title":"Design, synthesis and biological evaluation of novel C-29 carbamate celastrol derivatives as potent and selective cytotoxic compounds","volume":"139","author":"Figueiredo","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.ejmech.2017.06.029","article-title":"Novel celastrol derivatives with improved selectivity and enhanced antitumour activity: Design, synthesis and biological evaluation","volume":"138","author":"Figueiredo","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Valdeira, A.S.C., Ritt, D.A., Morrison, D.K., McMahon, J.B., Gustafson, K.R., and Salvador, J.A.R. (2018). Synthesis and Biological Evaluation of New Madecassic Acid Derivatives Targeting ERK Cascade Signaling. Front. Chem., 6.","DOI":"10.3389\/fchem.2018.00434"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1021\/acs.jnatprod.8b00864","article-title":"Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation","volume":"82","author":"Valdeira","year":"2019","journal-title":"J. Nat. Prod."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/8\/1219\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T11:57:58Z","timestamp":1785758278000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/8\/1219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":75,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["ph19081219"],"URL":"https:\/\/doi.org\/10.3390\/ph19081219","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]}}}